NCT07773142 Skeletal Muscle Adaptations to Peptide-Supplemented Resistance Exercise Training
| NCT ID | NCT07773142 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Birmingham |
| Condition | Supplement |
| Study Type | INTERVENTIONAL |
| Enrollment | 24 participants |
| Start Date | 2026-07-14 |
| Primary Completion | 2027-02 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 24 participants in total. It began in 2026-07-14 with a primary completion date of 2027-02.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Skeletal muscle size, an important metabolic tissue, is governed by the balance between two opposing processes, muscle protein synthesis and muscle protein breakdown. In response to long-term resistance exercise (weightlifting), skeletal muscle growth is commonly observed and it is believed that this is due to increases in muscle protein synthesis which leads to a positive net protein balance stimulating muscle growth. Due to its links to overall metabolic health, maximising muscle growth in response to resistance exercise training has become a significant focus in recent times, with various dietary supplements proposed due to their additive effects on muscle growth with resistance training. Protein supplementation, most commonly whey protein, is the most popular dietary supplement utilised by individuals completing resistance exercise training, however, more recent research has suggested that specific components of whey protein, as well as other foodstuffs, have the potential to individually activate growth pathways within skeletal muscle. This study will investigate whether daily supplementation with a combination of these compounds is able to produce greater muscle growth, compared to a placebo, when combined with resistance exercise training. We will also investigate whether this supplement can also produce greater increase in strength as well as studying the potential mechanisms behind any of these preferential adaptations in muscle samples which will be collected before and after the training period.
Eligibility Criteria
Inclusion Criteria: * Aged 18-35 years * Body Mass Index (BMI, calculated by research team based on height and weight) between 18.5-27.4 kg.m-2 * Meeting UK physical activity guidelines (150 mins moderate or 75 mins vigorous activity/week) * Not currently participating in structured progressive resistance exercise training or have regularly participated in previous 6 months * In good health, being free from disease or conditions (e.g., Type-II diabetes, hyper/hypothyroidism, irritable bowel syndrome, polycystic ovary syndrome) which influence skeletal muscle metabolism or digestion (self-declared) Exclusion Criteria: * Have an allergy to ingredients of the supplement or placebo supplement (e.g., legume/bean, corn allergies) * Have used dietary supplements which are known to affect skeletal muscle recovery and exercise adaptations (e.g., creatine) within the previous month * Are a smoker/vaper or have a history of smoking/vaping in previous year * Have a respiratory condition (e.g., asthma, chronic obstructive pulmonary disease) * Using hormone therapy (not including birth control), anabolic steroids, or recreational drugs * Are pregnant or currently breastfeeding * Are currently trying to conceive a child * Have any injury or body weakness which prevents participation in full body resistance exercise * Have a known allergy to lidocaine
Contact & Investigator
Nathan Hodson
PRINCIPAL INVESTIGATOR
University of Birmingham
Frequently Asked Questions
Who can join the NCT07773142 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 35 Years, studying Supplement. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07773142 currently recruiting?
Yes, NCT07773142 is actively recruiting participants. Contact the research team at n.w.hodson@bham.ac.uk for enrollment information.
Where is the NCT07773142 trial being conducted?
This trial is being conducted at Birmingham, United Kingdom.
Who is sponsoring the NCT07773142 clinical trial?
NCT07773142 is sponsored by University of Birmingham. The principal investigator is Nathan Hodson at University of Birmingham. The trial plans to enroll 24 participants.